Therefore, starting with TRPV1 and inhibiting abnormal activation of neuropeptides and microglia overproliferation may be a potential mechanism to inhibit central and peripheral sensitization and treat non-inflammatory pain in RA. The gene discussed is TRPV1; the disease is rheumatoid arthritis.